Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03340766
Title Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

relapsed/refractory diffuse large B-cell lymphoma

Therapies

Blinatumomab + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU


No variant requirements are available.